• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Meissa announces positive Phase 1c data from a study of its intranasal RSV vaccine in infants and toddlers

Meissa Vaccines is presenting Phase 1c data from a study of its MV-012-968 intranasal live attenuated RSV vaccine candidate in 66 children aged 6-36 months demonstrating that the highest dose of the vaccine evaluated induced an immune response in 89% of RSV-naïve subjects, with a serum neutralizing antibody response induced in 78% of the subjects. According to Meissa, the study found no serious adverse events, “negligible” viral shedding, and no difference in the rate of symptoms between the vaccine and placebo groups immediately following vaccination.

Meissa Vaccines Chief Scientific Officer Martin Moore said, “We are extremely pleased with the data from this clinical study in RSV-naïve infants and young children because Meissa’s pediatric live attenuated RSV vaccine demonstrated outstanding immunogenicity while also showing high attenuation and excellent safety. Live attenuated vaccines have historically provided broad and durable protection. These data clinically validate our AttenuBlock platform’s ability to generate live attenuated vaccines with outstanding immunogenicity and safety. Achieving both has previously been a major hurdle.”

CEO Frank Glavin commented, “The development of a safe and effective RSV vaccine is a significant global health priority that could save thousands of lives and protect the health of millions of children around the world. The clinical data we have generated from both our RSV and COVID-19 programs demonstrate the enormous potential of Meissa’s AttenuBlock platform to develop safe and effective intranasal live attenuated vaccines to protect against serious respiratory viruses, and we look forward to continuing to advance our vaccine candidates in clinical trials.”

Read the Meissa Vaccines press release.

Share

published on November 7, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews